Christopher J. Burns, Ph.D. is President and CEO at VenatoRx Pharmaceuticals, a leader in anti-infectives R&D. VenatoRx has executed a unique business model combining funding from the U.S. Government ($130M+) and private investors ($45M+) to invent and develop new, highly innovative anti-bacterial and anti-viral agents.
Dr. Burns has more than 25 years’ experience in the pharmaceutical industry including various corporate and R&D leadership positions at Protez Pharmaceuticals, ViroPharma, and Rhone-Poulenc Rorer (now Sanofi). Dr. Burns has appeared as co-author or co-inventor on more than 60 patents and publications and has served as Principal Investigator on more than ten awarded NIH grants. He received a B.S., Chemistry from St. Joseph’s University, and a Ph.D., Organic Chemistry from MIT under Nobel-laureate Professor K. Barry Sharpless. Dr. Burns currently serves on the Board of Directors at Life Sciences Pennsylvania (LSPA) and the Antimicrobials Working Group (AWG).